The relationship between follicle-stimulating hormone and metabolic dysfunction-associated fatty liver disease in men.
Humans
Male
Follicle Stimulating Hormone
/ blood
Middle Aged
Adult
Luteinizing Hormone
/ blood
Risk Factors
Sex Hormone-Binding Globulin
/ metabolism
Estradiol
/ blood
Non-alcoholic Fatty Liver Disease
/ blood
China
/ epidemiology
Case-Control Studies
ROC Curve
Biomarkers
/ blood
Fatty Liver
/ blood
Aged
Journal
Nutrition & diabetes
ISSN: 2044-4052
Titre abrégé: Nutr Diabetes
Pays: England
ID NLM: 101566341
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
17
10
2023
accepted:
04
07
2024
revised:
19
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
epublish
Résumé
The present study aimed to investigate the relationship between male hormones and metabolic dysfunction-associated fatty liver disease (MAFLD) in males. Data from the Fangchenggang Area Male Health and Examination Survey (FAMHES) were used to analyze the male hormone levels between MAFLD patients and controls. Univariate and multivariate logistic regression analyses were performed to identify risk factors for MAFLD. Receiver operating characteristic curve analysis was used to assess the diagnostic performance of male hormones for MAFLD. A total of 1578 individuals were included, with 482 individuals (30.54%) of MAFLD, including 293 (18.57%) with mild disease and 189 (11.98%) with moderate-to-severe disease. The MAFLD patients were significantly older than those without MAFLD. The LH, FSH, and SHBG levels in the MAFLD patients were significantly greater than those in the control group. Age, FSH, LH, SHBG, and estradiol were all risk factors for MAFLD. Age, FSH, and LH were risk factors for moderate-to-severe MAFLD. FSH was an independent risk factor for MAFLD and moderate-to-severe MAFLD. FSH showed an excellent diagnostic value, with an AUC of 0.992 alone and 0.996 after adjusting age. Our findings indicate that FSH may be a potential diagnostic and predictive biomarker for MAFLD.
Identifiants
pubmed: 38991999
doi: 10.1038/s41387-024-00314-1
pii: 10.1038/s41387-024-00314-1
doi:
Substances chimiques
Follicle Stimulating Hormone
9002-68-0
Luteinizing Hormone
9002-67-9
Sex Hormone-Binding Globulin
0
Estradiol
4TI98Z838E
Biomarkers
0
SHBG protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82002397
Informations de copyright
© 2024. The Author(s).
Références
Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1.
pubmed: 32044314
doi: 10.1053/j.gastro.2019.11.312
Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol. 2023;58:947–64.
pubmed: 37470858
pmcid: 10522746
doi: 10.1007/s00535-023-02021-7
Venkatesan K, Haroon NN. Management of metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am. 2023;52:547–57.
pubmed: 37495344
doi: 10.1016/j.ecl.2023.02.002
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–9.
pubmed: 32278004
doi: 10.1016/j.jhep.2020.03.039
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
pubmed: 26707365
doi: 10.1002/hep.28431
Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70:1119–33.
pubmed: 31070259
doi: 10.1002/hep.30702
Fouda S, Pappachan JM. Metabolic-associated fatty liver disease: a disastrous human health challenge. Endocrinol Metab Clin North Am. 2023;52:xv–xvi.
pubmed: 37495346
doi: 10.1016/j.ecl.2023.03.001
Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169:Itc65–itc80.
pubmed: 30398639
doi: 10.7326/AITC201811060
Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52:25–37.
pubmed: 33334622
doi: 10.1016/j.arcmed.2020.11.010
Fouda S, Jeeyavudeen MS, Pappachan JM, Jayanthi V. Pathobiology of metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am. 2023;52:405–16.
pubmed: 37495333
doi: 10.1016/j.ecl.2023.01.001
Kapoor N, Kalra S. Metabolic-associated fatty liver disease and diabetes: a double whammy. Endocrinol Metab Clin North Am. 2023;52:469–84.
pubmed: 37495338
doi: 10.1016/j.ecl.2023.02.006
Marschner RA, Arenhardt F, Ribeiro RT, Wajner SM. Influence of altered thyroid hormone mechanisms in the progression of metabolic dysfunction associated with fatty liver disease (MAFLD): a systematic review. Metabolites. 2022;12:675.
pubmed: 35893242
pmcid: 9330085
doi: 10.3390/metabo12080675
Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, et al. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713–33.
pubmed: 33982400
doi: 10.1111/liv.14943
Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol. 2021;17:662–70.
pubmed: 34417588
doi: 10.1038/s41574-021-00538-6
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457–69.
pubmed: 30924946
doi: 10.1002/hep.30626
Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5:673–81.
pubmed: 19859074
doi: 10.1038/nrendo.2009.212
Yang LJ, Zhou JZ, Zheng YF, Hu X, He ZY, Du LJ, et al. Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus. J Endocrinol Invest. 2023;46:1565–72.
pubmed: 36725809
doi: 10.1007/s40618-023-02006-6
Apostolov R, Wong D, Low E, Vaz K, Spurio J, Worland T, et al. Testosterone is lower in men with non-alcoholic fatty liver disease and alcohol-related cirrhosis and is associated with adverse clinical outcomes. Scand J Gastroenterol. 2023:1–7.
Sarkar M, Yates K, Suzuki A, Lavine J, Gill R, Ziegler T, et al. Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men. Clin Gastroenterol Hepatol. 2021;19:400–2.e2.
pubmed: 31812658
doi: 10.1016/j.cgh.2019.11.053
De Herdt C, De Block C, Francque S, Verrijken A, Van Dessel K, Van Gaal L, et al. A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity. Endocrine. 2023;80:54–63.
pubmed: 36857008
doi: 10.1007/s12020-022-03245-y
Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. PLoS ONE. 2021;16:e0251449.
pubmed: 34077443
pmcid: 8172043
doi: 10.1371/journal.pone.0251449
Mo MQ, Huang ZC, Yang ZH, Liao YH, Xia N, Pan L. Relationship between total testosterone, sex hormone-binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis. Ther Adv Endocrinol Metab. 2022;13:20420188221106879.
pubmed: 35785018
pmcid: 9240586
doi: 10.1177/20420188221106879
Hua X, Zhang H, Yang W, Liu G, Zhang S, Wang Y. SFI, a sex hormone binding globulin based nomogram for predicting non-alcoholic fatty liver disease in the Chinese population. Front Endocrinol. 2023;14:1176019.
doi: 10.3389/fendo.2023.1176019
Oduwole OO, Huhtaniemi IT, Misrahi M. The roles of luteinizing hormone, follicle-stimulating hormone and testosterone in spermatogenesis and folliculogenesis revisited. Int J Mol Sci. 2021;22:12735.
pubmed: 34884539
pmcid: 8658012
doi: 10.3390/ijms222312735
Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y. Associations between sex hormones and metabolic-associated fatty liver disease in a middle-aged and elderly community. Endocr J. 2022;69:1007–14.
pubmed: 35321990
doi: 10.1507/endocrj.EJ21-0559
Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, et al. Associations of sex steroids and sex hormone-binding globulin with non-alcoholic fatty liver disease: a population-based study and meta-analysis. Genes. 2022;13:966.
pubmed: 35741728
pmcid: 9223113
doi: 10.3390/genes13060966
Jung ES, Choi EK, Park BH, Chae SW. Serum follicle-stimulating hormone levels are associated with cardiometabolic risk factors in post-menopausal Korean women. J Clin Med. 2020;9:1161.
pubmed: 32325717
pmcid: 7230188
doi: 10.3390/jcm9041161
Bertone-Johnson ER, Virtanen JK, Niskanen L, Nurmi T, Ronkainen K, Voutilainen S, et al. Association of follicle-stimulating hormone levels and risk of type 2 diabetes in older postmenopausal women. Menopause. 2017;24:796–802.
pubmed: 28141661
doi: 10.1097/GME.0000000000000834
Wang N, Li Q, Han B, Chen Y, Zhu C, Chen Y, et al. Follicle-stimulating hormone is associated with non-alcoholic fatty liver disease in Chinese women over 55 years old. J Gastroenterol Hepatol. 2016;31:1196–202.
pubmed: 26678239
doi: 10.1111/jgh.13271
Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology. 2012;79:194–201.
pubmed: 21924462
doi: 10.1016/j.urology.2011.07.1399
Qin X, Lin L, Mo Z, Lv H, Gao Y, Tan A, et al. Reference intervals for serum alpha-fetoprotein and carcinoembryonic antigen in Chinese Han ethnic males from the Fangchenggang Area Male Health and Examination Survey. Int J Biol Markers. 2011;26:65–71.
pubmed: 21337313
doi: 10.5301/JBM.2011.6364
Qin X, Lv H, Mo Z, Chen Z, Lin L, Peng T, et al. Reference intervals for serum sex hormones in Han Chinese adult men from the Fangchenggang Area Male Health and Examination Survey. Clin Lab. 2012;58:281–90.
pubmed: 22582502
Cai J, Lin C, Lai S, Liu Y, Liang M, Qin Y, et al. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. Lipids Health Dis. 2021;20:145.
pubmed: 34706716
pmcid: 8549212
doi: 10.1186/s12944-021-01568-9
Qi N, Chen Y, Zeng Y, Bao M, Long X, Guo Y, et al. rs2274911 polymorphism in GPRC6A associated with serum E2 and PSA in a Southern Chinese male population. Gene. 2020;763:145067.
pubmed: 32827681
doi: 10.1016/j.gene.2020.145067
Meziri M, Pereira WC, Abdelwahab A, Degott C, Laugier P. In vitro chronic hepatic disease characterization with a multiparametric ultrasonic approach. Ultrasonics. 2005;43:305–13.
pubmed: 15737380
doi: 10.1016/j.ultras.2004.09.002
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–50.
pubmed: 12198701
doi: 10.1053/gast.2002.35354
Golan R, Scovell JM, Ramasamy R. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18:201–4.
pubmed: 26075536
pmcid: 4816459
doi: 10.3109/13685538.2015.1052392
Song MJ, Choi JY. Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin. Front Endocrinol. 2022;13:1053709.
doi: 10.3389/fendo.2022.1053709
Qiao S, Alasmi S, Wyatt A, Wartenberg P, Wang H, Candlish M, et al. Intra-pituitary follicle-stimulating hormone signaling regulates hepatic lipid metabolism in mice. Nat Commun. 2023;14:1098.
pubmed: 36841874
pmcid: 9968338
doi: 10.1038/s41467-023-36681-z
Zhu Y, Xu J, Zhang X, Ke Y, Fu G, Guo Q. A low follicle-stimulating hormone level is a protective factor for non-alcoholic fatty liver disease in older men aged over 80. BMC Geriatr. 2021;21:544.
pubmed: 34641807
pmcid: 8507128
doi: 10.1186/s12877-021-02490-6
Li X, Xin N, Guo T, Wu Z, Zheng Y, Lin L, et al. Follicle-stimulating hormone is negatively associated with nonalcoholic fatty liver disease in a Chinese elderly population: a retrospective observational study. BMC Endocr Disord. 2023;23:165.
pubmed: 37550673
pmcid: 10405433
doi: 10.1186/s12902-023-01427-x
Cohen DJ, Giaccagli MM, Herzfeld JD, González LN, Cuasnicú PS, Da Ros VG. Metabolic syndrome and male fertility disorders: Is there a causal link? Rev Endocr Metab Disord. 2021;22:1057–71.
pubmed: 34037916
doi: 10.1007/s11154-021-09659-9
Salvio G, Ciarloni A, Cutini M, Delli Muti N, Finocchi F, Perrone M, et al. Metabolic syndrome and male fertility: beyond heart consequences of a complex cardiometabolic endocrinopathy. Int J Mol Sci. 2022;23:5497.
pubmed: 35628307
pmcid: 9143238
doi: 10.3390/ijms23105497
Lotti F, Corona G, Degli Innocenti S, Filimberti E, Scognamiglio V, Vignozzi L, et al. Seminal, ultrasound and psychobiological parameters correlate with metabolic syndrome in male members of infertile couples. Andrology. 2013;1:229–39.
pubmed: 23315971
doi: 10.1111/j.2047-2927.2012.00031.x
Sermondade N, Faure C, Fezeu L, Shayeb AG, Bonde JP, Jensen TK, et al. BMI in relation to sperm count: an updated systematic review and collaborative meta-analysis. Hum Reprod Update. 2013;19:221–31.
pubmed: 23242914
doi: 10.1093/humupd/dms050
Martins AD, Majzoub A, Agawal A. Metabolic syndrome and male fertility. World J Mens Health. 2019;37:113–27.
pubmed: 30350486
doi: 10.5534/wjmh.180055
Craig JR, Jenkins TG, Carrell DT, Hotaling JM. Obesity, male infertility, and the sperm epigenome. Fertil Steril. 2017;107:848–59.
pubmed: 28366411
doi: 10.1016/j.fertnstert.2017.02.115
Nunes DC, Ribeiro JC, Alves MG, Oliveira PF, Bernardino RL. Male sex hormones, metabolic syndrome, and aquaporins: a triad of players in male (in)fertility. Int J Mol Sci. 2023;24:1960.
pubmed: 36768282
pmcid: 9915845
doi: 10.3390/ijms24031960
Christin-Maitre S, Young J. Androgens and spermatogenesis. Ann Endocrinol. 2022;83:155–8.
doi: 10.1016/j.ando.2022.04.010
Griswold MD. The central role of Sertoli cells in spermatogenesis. Semin Cell Dev Biol. 1998;9:411–6.
pubmed: 9813187
doi: 10.1006/scdb.1998.0203